https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33344 Wed 24 Nov 2021 15:52:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51850 Thu 21 Sep 2023 09:34:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19960 Sat 24 Mar 2018 07:58:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19790 Sat 24 Mar 2018 07:57:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26933 Opioid Treatment Index social functioning scale. Those classified in the highest quartile (score >6) were considered having lower social functioning. Analyses were performed using logistic regression. Results: Among 415 participants (mean age 41 years, 71% male), 24% were considered having lower social functioning, 70% had early HCV treatment intent (intention to be treated in the next 12 months), 53% were assessed by a specialist and 27% initiated treatment. Lower social functioning was independently associated with unemployment, unstable housing, recent injecting drug use and moderate to extremely severe symptoms of depression, anxiety and stress. Lower social functioning was independently associated with reduced early HCV treatment intent (aOR 0.51, 95% CI 0.30-0.84) and lower specialist assessment (aOR 0.48, 95% CI 0.29-0.79), but not HCV treatment uptake (aOR 0.76, 95% CI 0.40-1.43). Living with someone was independently associated with HCV treatment uptake (with someone and children: aOR 2.28, 95% CI 1.01-5.14; with someone and no children: aOR 2.36, 95% CI 1.30-4.31), but not early HCV treatment intent or specialist assessment. Conclusions: This study highlights the need for the development and implementation of strategies targeting people who inject drugs with lower social functioning to enhance HCV treatment intent and specialist assessment. Further, strategies to enhance social support may play a role in increasing HCV treatment uptake.]]> Sat 24 Mar 2018 07:27:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49510 Fri 19 May 2023 16:56:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24132 24weeks post-treatment). Findings: Among 101 treated, 37% (n=37) had recently injected drugs (past 6months) and 62% (n=63) were receiving OST. Adherence =80% was 86% (n=87). SVR was 74% (75 of 101), with no difference observed by sex (males: 76%, females: 67%, P=0.662). In adjusted analysis, age <35 (versus =45years) [adjusted odds ratio (aOR)=5.06, 95% confidence interval (CI)=1.47, 17.40] and on-treatment adherence =80% independently predicted SVR (aOR=19.41, 95% CI=3.61, 104.26]. Recent injecting drug use at baseline was not associated with SVR. Conclusions: People with a history of injecting drug use and chronic hepatitis C virus attending opioid substitution treatment and community health clinics can achieve adherence and responses to interferon-based therapy similar to other populations, despite injecting drugs at baseline. Younger age and adherence are predictive of improved response to hepatitis C virus therapy.]]> Fri 01 Apr 2022 09:25:51 AEDT ]]>